How India Exports Caffeine to the World

In the United States, caffeine is approved for medical use, particularly in the treatment of apnea of prematurity. The FDA approved Cafcit (caffeine citrate) injection on September 21, 1999, for this indication. Additionally, caffeine is included in combination products, such as the aspirin, butalbital, caffeine, and codeine phosphate capsules approved on March 5, 1999.

The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for caffeine-containing products, indicating a competitive generic market. As of March 2026, there are no active import alerts specifically targeting caffeine, suggesting compliance with FDA regulations among exporters. Given that 471 Indian exporters are actively involved in caffeine exports, adherence to FDA standards is crucial for market access.

In the European Union, caffeine citrate is authorized for medical use. Peyona, containing caffeine citrate, received EU-wide marketing authorization on July 2, 2009, for treating primary apnea of premature newborns. (ema.europa.eu) Similarly, Gencebok, another caffeine citrate product, was approved as a hybrid medicine, indicating its similarity to an existing authorized product but at a different strength. (ema.europa.eu)

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EU regulations, ensuring that caffeine-containing medicinal products meet stringent safety and efficacy standards. Compliance with Good Manufacturing Practice (GMP) requirements is mandatory for manufacturers exporting to these regions.

Caffeine citrate is included in the World Health Organization's Model List of Essential Medicines, underscoring its importance in neonatal care. The inclusion in the WHO list reflects its recognized efficacy and safety profile. Additionally, caffeine is monographed in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), providing standardized quality benchmarks for its production and quality control.

In India, caffeine is regulated by the Central Drugs Standard Control Organisation (CDSCO). It is classified under Schedule H, indicating that it is a prescription drug requiring medical supervision. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), monitors the pricing of essential medicines, including caffeine formulations. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) to ensure compliance with export regulations.

The primary patents for caffeine-based medicinal products have expired, leading to a robust generic market. This expiration has facilitated the entry of multiple generic manufacturers, enhancing competition and accessibility.

In June 2025, the FDA updated its guidance on the labeling requirements for caffeine-containing products, emphasizing clearer dosage instructions to prevent misuse. This regulatory change impacts exporters by necessitating revisions to product labeling to align with the new standards.

In September 2025, the European Medicines Agency (EMA) initiated a review of caffeine citrate products to assess their safety profile in neonatal care. The outcome of this review may influence market dynamics and regulatory requirements for exporters targeting the EU market.

In December 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of caffeine citrate for neonatal apnea treatment. This inclusion underscores the global recognition of caffeine's therapeutic value and may influence procurement policies in various countries.

In February 2026, the NPPA in India revised the ceiling price for caffeine formulations under the DPCO, affecting pricing strategies for domestic manufacturers and exporters. Compliance with the new pricing regulations is essential for market access and profitability.

In March 2026, the CDSCO issued new guidelines for the export of pharmaceutical products, including caffeine, emphasizing the need for stringent quality control measures and documentation. Exporters must adhere to these guidelines to ensure uninterrupted access to international markets.

These developments highlight the dynamic regulatory environment surrounding caffeine exports and underscore the importance of continuous monitoring and compliance for Indian exporters.

India's pharmaceutical industry, often termed the "pharmacy of the world," heavily relies on imports for Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs). Approximately 70% of APIs used in Indian drug formulations are sourced from China, underscoring a significant dependency on Chinese suppliers. This reliance extends to KSMs, the foundational chemicals in drug synthesis, with China controlling a substantial portion of the global KSM supply.

Recent geopolitical tensions have exacerbated this vulnerability. In February 2026, the closure of the Strait of Hormuz disrupted global supply chains, leading to increased costs and delays in raw material shipments. Such events highlight the risks associated with concentrated sourcing and the need for diversification in supply chains.

TransData Nexus's proprietary trade data reveals that the top five exporters of caffeine from India account for 42.1% of total exports, with ADCOCK INGRAM LIMITED alone contributing 20.7%. This concentration indicates a moderate risk, as disruptions affecting these key suppliers could significantly impact the global caffeine supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to bolster domestic API and KSM production. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules, reducing import dependence. While these initiatives are promising, their effectiveness in diversifying the supplier base and reducing single-source risks will require time to materialize.

The closure of the Strait of Hormuz in February 2026, following military actions involving Iran, the US, and Israel, has had profound implications for global supply chains. Approximately 20% of the world's oil transits through this chokepoint, and its disruption has led to increased energy costs and logistical challenges. These factors have cascaded into the pharmaceutical sector, affecting manufacturing costs and the timely delivery of products.

Additionally, tensions in the Red Sea region have further strained shipping routes, leading to delays and increased freight costs. Such geopolitical events underscore the fragility of global supply chains and the importance of strategic planning to mitigate potential disruptions.

• Diversify Supplier Base: Encourage the development of alternative suppliers for APIs and KSMs to reduce dependency on a single country or region.

• Enhance Domestic Production: Accelerate initiatives like the PLI scheme to strengthen domestic manufacturing capabilities for critical pharmaceutical ingredients.

• Strengthen Supply Chain Monitoring: Implement robust systems to monitor geopolitical developments and assess their potential impact on supply chains in real-time.

• Develop Contingency Plans: Establish comprehensive contingency plans, including alternative shipping routes and inventory management strategies, to address potential disruptions.

• Foster International Collaboration: Engage in partnerships with other countries to share resources and information, enhancing collective resilience against supply chain disruptions.

RISK_LEVEL: MEDIUM